MedTrace Logo

SB17170 Phase1 Trial in Healthy Volunteer

NCT05795192 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-03-21

No results posted yet for this study

Summary

This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults.

The main questions it aims to answer are the safety, tolerability, and PK characteristics of SB17170 in healthy adults.

Conditions

  • Safety Issues
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics

Interventions

DRUG

SB17170

Taking SB17170 orally once a day

DRUG

Placebo

Taking Placebo orally once a day

Sponsors & Collaborators

  • SPARK Biopharma

    lead INDUSTRY

Principal Investigators

  • SeungHwan Lee, M.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2024-02-29
Completion
2024-03-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05795192 on ClinicalTrials.gov